Sun Pharmaceuticals Industries Ltd
SUNPHARMA

535.75

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)

535.60

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)

532.15

Open ()
Open Interest
(Contracts)
VWAP ()
Day's Vol
(shares)
Detailed Quote
Period From
Period To
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 26-Jul-2017 - -
Dear Sirs, 1. This is to inform you that a meeting of the Board of Directors of the Company will be held on Friday, August 11, 2017 to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. 2. In view of the consideration of above, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from Wednesday, August 2, 2017 to Wednesday, August 16, 2017 (both days inclusive). This is for your information and record. The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the first quarter ended June 30, 2017 which are enclosed herewith along with the Limited Review Report of the Auditors on Standalone and Consolidated Financial Results. The meeting of the Board of Directors commenced at 10:50 a.m. and concluded at 3:20 p.m. This is for your information and record. (As Per BSE Announcement Dated On 11/08/2017)
Board Meeting - 11-May-2017 - -
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 26, 2017, inter alia, to transact the following business:1. To consider and approve standalone and consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2017.2. To consider recommendation of dividend for the year ended March 31, 2017 subject to the approval of the shareholders at the ensuing Annual General Meeting.Further, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from May 17, 2017 to May 30, 2017 (both days inclusive). Dear Sirs, This is to inform you that a meeting of the Board of Directors of the Company will be held on Friday, May 26, 2017, interalia, to transact the following business : (i) To consider and approve standalone and consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2017. (ii) To consider recommendation of dividend for the year ended March 31, 2017 subject to the approval of the shareholders at the ensuing Annual General Meeting. Further, kindly note that window closure for trading by designated persons as per Insider Trading Rules of the Company will be from Wednesday, May 17, 2017 to Tuesday, May 30, 2017 (both days inclusive). This is for your information and record. Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 26, 2017, inter alia, to transact the following business: 1. To consider and approve standalone and consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2017. 2. To consider recommendation of dividend for the year ended March 31, 2017 subject to the approval of the shareholders at the ensuing Annual General Meeting. Further, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from May 17, 2017 to May 30, 2017 (both days inclusive). Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2017, inter alia, has recommended payment of dividend of Rs. 3.5/- (Rupees Three and Fifty Paise Only) per equity share of Re. 1/- each of the Company for the year ended March 31, 2017, subject to the approval of the members at the ensuing Annual General Meeting of the Company.The dividend is expected to be paid on or about last week of September, 2017. 1. The Board of Directors of the Company at its meeting held today approved and took on record the Financial Results for Fourth Quarter and Annual Audited Standalone and Consolidated Financial Results for the year ended March 31, 2017. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following as Annexure I: a) Financial Results for Fourth Quarter and Annual Audited Standalone and Consolidated Financial Results the year ended March 31, 2016. b) Auditors Report on Standalone and Consolidated Financial Results. c) Declaration regarding Audit Report with unmodified opinion. 2. The Board of Directors of the Company at their meeting held today recommended payment of dividend of Rs. 3.5/- (Rupees Three and Fifty Paise Only) per equity share of Re.1/- each of the Company for the year ended March 31, 2017, subject to the approval of the members at the ensuing Annual General Meeting of the Company. The dividend is expected to be paid on or about last week of September, 2017. 3. The Board of Directors of the Company at their meeting held today approved Re-appointment of Mr. Dilip Shanghvi as the Managing Director of the Company for a term of five years from April 1, 2018 to March 31, 2023, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting. The brief profile of Mr. Dilip Shanghvi, as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure II. Mr. Dilip Shanghvi is brother-in-law of Mr. Sudhir Valia, who is a Whole-time Director of the Company. 4. The Board of Directors of the Company at their meeting held today have accepted the resignation of Mr. Uday Baldota as the Chief Financial Officer of the Company w.e.f. June 19, 2017 since he would be shifting to United States of America, to look after the business of Taro Pharmaceutical Industries Limited, a subsidiary of the Company and the Board of Directors have appointed Mr. C. S. Muralidharan as the Chief Financial Officer of the Company w.e.f. June 19, 2017. The profile of Mr. C. S. Muralidharan as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as Annexure III. The meeting of the Board of Directors commenced on May 26, 2017 at 10:45 a.m. and concluded at 4:30 p.m. (As Per BSE Announcement Dated on 5/26/2017) Sub: A small correction in the profile of the Chief Financial Officer of the Company sent to the Exchanges on May 26, 2017 along with the Outcome of the Board Meeting held on May 26, 2017 Please note that while submitting the profile of the Chief Financial Officer of the Company who is joining our Company with effect from 19th June,17 in Annexure III to the letter for the outcome of the board meeting held on May 26, 2017, there was an error in mentioning about he being a member of the Institute of Company Secretaries of India . Please find here with the corrected & revised Profile of Mr. C. S. Muralidharan, replacing the earlier one. We are sorry for the inconvenience, if any caused in this regard. This is for your information and record. (As Per BSE Announcement Dated on 30.05.2017)
Board Meeting - 27-Jan-2017 - -
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 14, 2017, to consider and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2016 (Q3). In view of the consideration of above, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from February 03, 2017 to February 16, 2017 (both days inclusive). Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2017, inter alia, has approved the following; 1. The Board of Directors of the Company appointed Mr. Kalyanasundaram Subramanian as an Additional Director of the Company with immediate effect. 2. The Board of Directors of the Company have, subject to the approval of the members of the Company at the ensuing General Meeting of the Company, appointed Mr. Kalyanasundaram Subramanian as the Whole time Director of the Company, without any remuneration, for a period of two (2) years from February 14, 2017 to February 13, 2019. Mr. Kalyanasundaram Subramanian is not related to any of the Directors of the Company. (As Per BSE Announcement Dated on 14.02.2017)
Board Meeting - 24-Oct-2016 - -
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 10, 2016, inter alia, to transact the following business: 1. To consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016 (Q2). 2. To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited (formerly known as Solrex Pharmaceutical Company), all four companies being wholly owned subsidiaries of Sun Pharmaceutical Industries Ltd., with Sun Pharmaceutical Industries Ltd subject to receipt of necessary approvals. Further, in view of the consideration of above items, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from November 01, 2016 to November 14, 2016 (both days inclusive). Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 10, 2016, has approved subject to receipt of further approvals of the honble High Court of Gujarat or the National Company Law Tribunal (High Court), as the case may be, Stock Exchanges, Securities and Exchange Board of India and all other requisite parties/authorities, the Scheme of Arrangement for amalgamation of Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited and Vidyut Investments Limited, which are direct or indirect wholly owned subsidiaries of the Company, into Sun Pharmaceutical Industries Limited in terms of Sections 391 to 394 or any other applicable provisions, if any, of the Companies Act, 1956 and/or the corresponding provisions of Companies Act, 2013 (Scheme), as the case may be, with appointed date of April 01, 2017 or such other date as may be agreed/required by the Transferor Companies and the Transferee Company and/or by the High Court. The meeting of the Board of Directors commenced on November 10, 2016 at 11:00 a.m. and concluded at 03:25 p.m. (As Per BSE Announcement Dated On 10/11/2016)